Literature DB >> 27234929

Intraocular Pressure Reduction after Phacoemulsification versus Manual Small-Incision Cataract Surgery: A Randomized Controlled Trial.

Sabyasachi Sengupta1, Rengaraj Venkatesh2, Palaniswamy Krishnamurthy1, Manas Nath1, Abha Mashruwala1, Pradeep Y Ramulu3, Alan L Robin4, Paul Lee5.   

Abstract

PURPOSE: To compare reduction in intraocular pressure (IOP) and change in anterior chamber angle configuration between eyes undergoing phacoemulsification versus those undergoing manual small-incision cataract surgery (MSICS).
DESIGN: Prospective, randomized, double-masked, parallel assignment clinical trial. PARTICIPANTS: Five hundred eyes of 500 participants 40 to 70 years of age with normal IOP, gonioscopically open angles, and age-related cataract.
METHODS: Eyes underwent phacoemulsification or MSICS after a 1:1 randomization and allocation code. Best-corrected vision, IOP, comprehensive slit-lamp evaluation, and anterior segment (AS) optical coherence tomography (OCT) were performed at baseline and at 1, 3, and 6 months follow-up. MAIN OUTCOME MEASURES: Change in IOP (ΔIOP) and AS OCT parameters between baseline and 6 months after surgery.
RESULTS: Six months, similar IOP reduction was observed in eyes undergoing phacoemulsification (ΔIOP = 2.7±2.9 mmHg) and MSICS (ΔIOP = 2.6±2.6 mmHg; P = 0.70). Widening of the angle opening distance (AOD) 500 μm from the scleral spur (median ΔAOD500 = 103 μm; interquartile range = 39-179 μm) was also similar in both groups (P = 0.28). Multivariate linear regression analysis showed that eyes with higher baseline IOP experienced significantly greater reduction in IOP at 6 months (ΔIOP = 0.46-mmHg reduction for every 1-mmHg increment in baseline IOP; 95% confidence interval [CI], 0.4-0.5 mmHg; P < 0.001). After adjusting for covariates, the magnitude of widening of AOD500 was not associated significantly with reduction in IOP (1.33-mmHg reduction for every 1-mm increment in AOD500; P = 0.07). Baseline AOD500 (β = -0.60-mm change/1-mm increment of baseline AOD; 95% CI, -0.67 to -0.53 mm) and anterior chamber depth (β = 0.07-mm change/1-mm increment of baseline anterior chamber depth; 95% CI, 0.04-0.1 mm) were significant predictors of AOD500 widening at 6 months.
CONCLUSIONS: Both phacoemulsification and MSICS led to significant and similar IOP reductions 6 months after surgery, and both surgeries produced similar changes in anterior chamber and angle parameters. Higher baseline IOP was associated with greater IOP reduction; IOP reduction also can be attributed partly to changes in angle and anterior chamber configuration, although these parameters were unable to predict significantly predict IOP drop at 6 months.
Copyright © 2016 American Academy of Ophthalmology. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27234929     DOI: 10.1016/j.ophtha.2016.04.014

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  12 in total

1.  [Effect of different clear corneal incision sites on surgery efficacy and anterior segment parameters in patients undergoing phacoemulsification].

Authors:  Lijun Wang; Xiting Yang; Yi Zhang; Dingying Liao; Lin Zhao; Jianming Wang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-12-30

2.  Clinical outcome of phacoemulsification combined with intraocular lens implantation for primary angle closure/glaucoma (PAC/PACG) with cataract.

Authors:  Yuan He; Ruixue Zhang; Chuntao Zhang; Jun Jia; Huifeng Liu; Beilei He; Zhuoya Quan; Jian Zhang
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

3.  Outcomes after combined excisional goniotomy and manual small incision cataract surgery.

Authors:  Daniela Alvarez-Ascencio; Gabriel Lazcano-Gomez; Malik Y Kahook
Journal:  Int J Ophthalmol       Date:  2022-10-18       Impact factor: 1.645

4.  Predictors of Intraocular Pressure After Phacoemulsification in Primary Open-Angle Glaucoma Eyes with Wide Versus Narrower Angles (An American Ophthalmological Society Thesis).

Authors:  Shan C Lin; Marisse Masis; Travis C Porco; Louis R Pasquale
Journal:  Trans Am Ophthalmol Soc       Date:  2017-10-23

5.  [Prediction of postoperative visual acuity in cataract patients with idiopathic macular epiretinal membrane by hand-held retinal optometer and optical coherence tomography].

Authors:  Hongyang Li; Yanying Li; Liping Xue; Honglei Zou; Renlong Liang; Binghua Yang; Yi Wu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-01-30

6.  Intraocular pressure variation after conventional extracapsular cataract extraction, manual small incision cataract surgery and phacoemulsification in an indigenous black population.

Authors:  Oluwatoyin Helen Onakpoya; Adenike Odunmorayo Adeoye; Bernice Oluwakemi Adegbehingbe; Sarat Abolore Badmus; Bolajoko Abidemi Adewara; Oluwaseun Olaniyi Awe; Patrick Agadaigho Udonwa
Journal:  Pan Afr Med J       Date:  2020-06-23

7.  Post-phacoemulsification iris changes in eyes with glaucoma or glaucoma suspect status.

Authors:  Qinyun Wang; Claudio I Perez; Marissé Masis; Max Feinstein; Marta Mora; Shan C Lin; Yen C Hsia
Journal:  PLoS One       Date:  2018-12-13       Impact factor: 3.240

8.  Intraocular Pressure and Anterior Segment Morphometry Changes after Uneventful Phacoemulsification in Type 2 Diabetic and Nondiabetic Patients.

Authors:  João N Beato; David Reis; João Esteves-Leandro; Manuel Falcão; Vítor Rosas; Ângela Carneiro; Fernando Falcão Reis
Journal:  J Ophthalmol       Date:  2019-06-10       Impact factor: 1.909

9.  Intraocular Pressure Reduction after Femtolaser Assisted Cataract Surgery and Its Association with the Use of Ultrasound.

Authors:  Hana Abouzeid; Walter Ferrini; Murielle Bochud
Journal:  Medicina (Kaunas)       Date:  2021-05-01       Impact factor: 2.430

10.  Efficacy and safety of phacoemulsification plus goniosynechialysis and trabectome in patients with primary angle-closure glaucoma.

Authors:  Yu Wang; Zhi-Qiao Liang; Yu Zhang; Lauren Hennein; Ying Han; Hui-Juan Wu
Journal:  Sci Rep       Date:  2021-07-06       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.